Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.80 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | BLM | P54132 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.68 |
| ▸ | APEX1 | P27695 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin 51 SCHEMBL1704811 | 1.00 | EGFR (0.80) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL25736026 | 0.91 | EGFR (0.68) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL25737631 | 0.83 | EGFR (1.00) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL17610618 | 0.77 | ALDH1A1 (1.00) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL10144540 | 0.77 | ALDH1A1 (1.00) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL1705596 | 0.77 | ALDH1A1 (1.00) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL13928220 | 0.76 | EGFR (0.64) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL25736027 | 0.75 | EGFR (0.83) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL6046312 | 0.75 | KDM4E (0.72) | EGFRMEN1KMT2AMAPTBLM | |
| SCHEMBL6046314 | 0.75 | KDM4E (0.72) | EGFRMEN1KMT2AMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4577832-A1 | METHOD FOR PREDICTING THE RESPONSE TO AN INHIBITOR OF EGFR KINASE ACTIVITY | Indivumed GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2020-10-29 | — | — | US | claimed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2019-05-02 | — | — | US | claimed |
| WO-2015095807-A1 | CANCER TREATMENTS USING COMBINATIONS OF EGFR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | PARIS SCIENCES ET LETTRES (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
| US-20100112693-A1 | Differentiation of Human Embryonic Stem Cells | CENTOCOR ORTHO BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010051223-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | CENTOCOR ORTHO BIOTECH INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20080146584-A1 | Method of treating cancers using beta-lapachone or analogs or derivatives thereof | LI CHIANG | 2008-06-19 | — | — | US | disclosed |
| US-20080146584-A1 | Method of treating cancers using beta-lapachone or analogs or derivatives thereof | LI CHIANG | 2008-06-19 | — | — | US | disclosed |
| US-7361691-B2 | Method of treating cancers using β-lapachone or analogs or derivatives thereof | ARQULE, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361691-B2 | Method of treating cancers using β-lapachone or analogs or derivatives thereof | ARQULE, INC. (US) | 2008-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885MEN1 63/4885KMT2A 2938/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | EGFR 4770/4885MEN1 3922/4885KMT2A 1009/4885 |
| US-20080146584-A1 | Method of treating cancers using beta-lapachone or analogs or derivatives thereof | SKP2, CDC25C, CDK1 | EGFR 961/4885MEN1 2685/4885KMT2A 1962/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | EGFR 3015/4885MEN1 2427/4885KMT2A 3355/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885MEN1 63/4885KMT2A 2938/4885 |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | BLVRB, HBG2, Q6ZSR9 | EGFR 3564/4885MEN1 3100/4885KMT2A 1218/4885 |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885MEN1 63/4885KMT2A 2938/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885MEN1 63/4885KMT2A 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.